US 12,473,367 B2
Bispecific agonistic antibodies to activin a receptor like type 1 (ALK1)
Alexey Alexandrovich Lugovskoy, Belmont, MA (US); Jean-Christophe Hus, Concord, MA (US); and Melissa Geddie, Arlington, MA (US)
Assigned to DIAGONAL THERAPEUTICS INC., Cambridge, MA (US)
Filed by DIAGONAL THERAPEUTICS INC., Cambridge, MA (US)
Filed on Apr. 29, 2025, as Appl. No. 19/193,079.
Application 19/193,079 is a continuation of application No. 18/628,187, filed on Apr. 5, 2024.
Claims priority of provisional application 63/596,899, filed on Nov. 7, 2023.
Claims priority of provisional application 63/537,318, filed on Sep. 8, 2023.
Claims priority of provisional application 63/458,044, filed on Apr. 7, 2023.
Prior Publication US 2025/0257140 A1, Aug. 14, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 3/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61P 3/00 (2018.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/75 (2013.01); C07K 2317/94 (2013.01)] 4 Claims
 
1. A multispecific binding protein comprising a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 142, and a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 146.